Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Epstein-Barr virus gp350 ferritin nanoparticle vaccine
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
The Epstein-Barr virus (EBV) gp350 ferritin nanoparticle vaccine is an investigational prophylactic vaccine designed to prevent EBV infection and its associated complications, such as infectious mononucleosis, multiple sclerosis, and various malignancies (e.g., Hodgkin lymphoma, Burkitt lymphoma, and nasopharyngeal carcinoma). Developed by the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Diseases in collaboration with the NIAID Vaccine Research Center, the vaccine consists of the EBV envelope glycoprotein gp350 fused to self-assembling Helicobacter pylori non-heme ferritin. This fusion protein self-assembles into a spherical nanoparticle that displays the gp350 antigen in a dense, highly immunogenic array. The vaccine is formulated with Novavax's saponin-based Matrix-M (or Matrix-M1) adjuvant to enhance immune responses. In Phase I/II clinical trials, the vaccine has demonstrated a favorable safety profile and elicited robust neutralizing antibody titers and polyfunctional CD4+ and CD8+ T-cell responses in both EBV-seropositive and EBV-seronegative healthy adults.
- Other names
- EBV gp350-FerritinEBV gp350-ferritin nanoparticle vaccineEBV gp350-ferritin vaccineEpstein-Barr virus gp350-ferritin nanoparticle vaccineEpstein-Barr virus gp350-ferritin nanoparticle vaccine with saponin-based adjuvant
02
Targets
CR1 (Complement receptor type 1)CR2 (Complement receptor type 2)gp350 (Epstein-Barr virus glycoprotein 350)
Beyond the preview
Go deeper on Epstein-Barr virus gp350 ferritin nanoparticle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Epstein-Barr virus gp350 ferritin nanoparticle vaccine.